All In Biotech

Drug Trial Radar · NCT02643550

Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 1b/2 Trial of IPH2201 And Cetuximab in Patients With Human Papillomavirus (HPV) (+) and HPV (-) Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Last checked: Nov 20, 2026Latest source record: May 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

143

Actual

Start

Dec 2015

Primary completion

Mar 28, 2023

Study completion Mar 28, 2023

Sponsor

Lead sponsor
Innate PharmaIndustry
Sponsor type
Industry
Collaborators
AstraZeneca
First posted
Dec 31, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to evaluate in a 3 +3 design, the safety of escalating doses of Monalizumab given IV in combination with cetuximab in patients who have received prior systemic regimen(s) for recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). Cohorts expansion will evaluate antitumor activity of monalizumab and cetuximab with or without anti-PD(L)1

Conditions

  • Head and Neck Neoplasms

Interventions

  • MonalizumabBiological

  • CetuximabBiological

  • Anti-PD(L)1Biological

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of Dose Limiting Toxicities (DLT) in the dose escalation part of the studyTime frame: within 4 weeks after first administration
  2. Objective Response Rate for expansion cohortsTime frame: up to 12 months

Locations

18 sites in 2 countries. Site status is shown where the registry gives one.

  • University of California, Moores Cancer Center

    La Jolla, California

  • Stanford Cancer Center

    Stanford, California

  • University of Chicago

    Chicago, Illinois

  • University of Maryland, Greenebaum Comprehensive Cancer Center

    Baltimore, Maryland

  • Washington University School of Medicine

    St Louis, Missouri

  • Icahn School of Medicine at Mount Sinaï

    New York, New York

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Centre Jean Perrin

    Clermont-Ferrand, France

  • Centre Oscar Lambret

    Lille, France

  • Centre Leon Berard

    Lyon, France

  • Hopital La Timone

    Marseille, France

  • Institut Regional du Cancer de Montpellier

    Montpellier, France

  • Centre Antoine Lacassagne

    Nice, France

  • Centre Eugene Marquis

    Rennes, France

  • ICO Rene Gauducheau

    Saint-Herblain, France

  • Institut Gustave Roussy

    Villejuif, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.